The World Health Organisation (WHO) has published its first-ever global guidelines on the diagnosis and management of type 1 diabetes in adults, warning that millions of patients still lack access to affordable insulin and essential care more than a century after the lifesaving drug was discovered.
Released to commemorate World Diabetes Day 2026 under the theme “Early action on diabetes,” the framework provides evidence-based clinical recommendations for managing the lifelong condition across diverse healthcare settings—including low-resource countries and regions experiencing emergencies or humanitarian crises.
According to the global health body, the new guidelines aim to close persistent care gaps around insulin availability, regular blood glucose monitoring, and specialised treatment for adults who depend on daily insulin to survive.
WHO figures indicate that an estimated 9.5 million people were living with type 1 diabetes globally in 2025, with another 500,000 newly diagnosed during the year. While often regarded as a childhood illness, WHO noted that type 1 diabetes is increasingly affecting adults, highlighting the urgent need to expand diagnostic and treatment systems beyond paediatric care.
”Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin,” said WHO Director of Noncommunicable Diseases and Mental Health, Dr Søren Brostrøm.
”The new WHO guidelines provide evidence-based recommendations to help countries deliver the best possible care, including in settings where resources are limited and health services are disrupted.”
Core Treatment and Monitoring Recommendations
Under the new guidelines, adults living with type 1 diabetes are advised to receive multiple daily insulin injections, with doses adjusted according to their blood glucose levels. WHO affirmed that manufactured human insulin remains an appropriate and effective baseline therapy, while other types of insulin may be used where clinically necessary.
The recommendations also call for consistent blood sugar tracking through:
Clinic-based testing: Periodic laboratory checks to measure average blood glucose levels over several months.
Home monitoring: Self-testing via finger-prick devices or continuous glucose monitors equipped with small skin sensors.
Alternative screening: Urine glucose testing in low-resource settings where blood glucose testing is unavailable.
Driving 2030 Targets Amid Rising Global Burden
WHO said the guidelines will support its 2030 global targets of guaranteeing universal access to affordable insulin treatment and blood glucose self-monitoring. The agency pledged to equip countries with practical implementation tools and progress-tracking frameworks, while encouraging governments to involve people living with type 1 diabetes in designing, implementing, and evaluating national care programmes.
The release comes against the backdrop of a rapidly escalating global diabetes crisis. WHO warned that unmanaged diabetes can trigger severe, life-threatening complications, including blindness, kidney failure, heart attacks, stroke, and lower-limb amputation.
Worldwide diabetes prevalence has more than quadrupled since 1990, reaching an estimated 830 million cases globally in 2022—the vast majority of whom live with type 2 diabetes. Alarmingly, more than 40 per cent of people living with the disease remain unaware of their status and undiagnosed.



